Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond

State‐of‐the‐art document on optimal contemporary management of cardiomyopathies

“…The optimal positioning of mavacamten in the obstructive HCM treatment algorithm is yet unresolved. Due to the high starting price and caution required with the first‐in‐class negative inotrope, the drug will plausibly be indicated in patients with obstructive HCM who fail to respond to traditional drug regimens but are not immediate candidates or are not motivated for surgical or interventional options 147 . Further studies are needed to assess the long‐term efficacy, tolerability and economic sustainability of mavacamten in obstructive HCM, as well as its potential impact on long‐term outcomes.…”

Effectiveness of 2014 ESC HCM-Risk-SCD score in prediction of appropriate implantable-cardioverter-defibrillator shocks

“…Therefore, although the HCM-Risk-SCD score remains a well recognized tool for patients' risk stratification as in EVIDENCE-HCM, 8 clinicians should be aware of its limitations when giving ICD indications. The score should always be integrated with a multidisciplinary evaluation, 9,10 including radiological findings and potentially, in the near future, genetic assessment to promote a proper patient-tailored approach. 11…”

Cardiac Sarcomere Signaling in Health and Disease

“…Aficamten (IC 10: 0.8 µM to IC 50 7.9 µM) shows a larger effective concentration range than Mavacamten (IC 10: 0.6 µM to IC 50: 1.7 µM) in vivo, suggesting that it may have a safer range of dosing [194]. Aficamten has been in multiple clinical trials with promising preliminary results but is still in process of getting authorization [195].…”